Tacrolimus

Generic Name
Tacrolimus
Brand Names
Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
Drug Type
Small Molecule
Chemical Formula
C44H69NO12
CAS Number
104987-11-3
Unique Ingredient Identifier
Y5L2157C4J
Background

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...

Indication

Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...

Associated Conditions
Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
Associated Therapies
-
Clinical Trials
Related News

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

First Posted Date
2003-10-07
Last Posted Date
2018-06-12
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
121
Registration Number
NCT00070135
Locations
🇺🇸

New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States

🇺🇸

Mount Sinai Medical Center, New York, New York, United States

🇺🇸

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 18 locations

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

First Posted Date
2003-07-14
Last Posted Date
2013-12-05
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
668
Registration Number
NCT00064701

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

First Posted Date
2003-05-09
Last Posted Date
2013-07-10
Lead Sponsor
Chimeric Therapies
Registration Number
NCT00004255
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States

🇺🇸

Presbyterian-St Luke's Medical Center, Denver, Colorado, United States

and more 12 locations

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

First Posted Date
2003-02-06
Last Posted Date
2020-02-10
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
41
Registration Number
NCT00053989
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

First Posted Date
2003-01-28
Last Posted Date
2016-07-01
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
82
Registration Number
NCT00053196
Locations
🇺🇸

Union Hospital Cancer Center at Union Hospital, Elkton MD, Maryland, United States

🇺🇸

Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees, New Jersey, United States

and more 9 locations

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

Phase 3
Completed
Conditions
Graft Versus Host Disease
First Posted Date
2003-01-27
Last Posted Date
2014-02-14
Lead Sponsor
Children's Oncology Group
Target Recruit Count
82
Registration Number
NCT00031824
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

All Children's Hospital, St. Petersburg, Florida, United States

🇺🇸

Maine Children's Cancer Program, Scarborough, Maine, United States

and more 100 locations

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-03-07
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00014469
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

Phase 2
Withdrawn
Conditions
Kidney Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-07-11
Lead Sponsor
Fox Chase Cancer Center
Registration Number
NCT00025519

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

First Posted Date
2003-01-27
Last Posted Date
2010-10-01
Lead Sponsor
Temple University
Target Recruit Count
10
Registration Number
NCT00002809
Locations
🇺🇸

Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders

First Posted Date
2003-01-27
Last Posted Date
2010-04-02
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT00002792
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy